Clinical Trial Update: Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial investigating SGM-101 for delineating primary, recurrent tumors and metastases in colorectal cancer surgery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms

Drugs mentioned

• SGM-101

Snippet

Sponsor: Surgimab | Conditions: Colorectal Neoplasms | Phase 3 | Status: RECRUITING